Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
The dangers of this are under consuming calories and nutrients, and developing anemia, kidney and liver failure, cardiac problems and other health risks.